Role of thrombopoietin stimulating agents (Eltrombopag and Romiplostim) in immune thrombocytopenia secondary to SLE
DOI:
https://doi.org/10.17533/udea.iatreia.100Keywords:
lupus erythematosus, systemic, purpura, thrombocytopenic, idiopathic, receptors, thrombopoietinAbstract
Introduction: Immune thrombocytopenia is a frequent hematologic manifestation in systemic lupus erythematosus (SLE). Corticosteroids are the first line of treatment for moderate to severe thrombocytopenia in this disease, in conjunction with antimalarials or other immunosuppressants. In particular cases where the response to initial interventions is not achieved, second-line therapies with different mechanisms of action re available.
Objective: This narrative review will focus on two thrombopoietin receptor agonist drugs (TPO-RA): eltrombopag and romiplostim, and their role in immune thrombocytopenia secondary to SLE. In addition, its pharmacological profile, dose and indications will be reviewed in the context of this disease.
Methods: A literature search was conducted in different databases; scientific articles and guidelines were nalyzed, both for SLE and immune thrombocytopenia. With the purpose of answering different clinical questions that constantly arise in the scene of daily practice.
Results and conclusions: The use of TPO-RA stimulants is a therapeutic alternative for particular scenarios in patients with SLE and immune thrombocytopenia, however studies focused on this particular population are necessary to be able to make strong recommendations about its utility. Current data are extrapolated from primary immune thrombocytopenia.
Downloads
References
(1) Maroun MC, Ososki R, Andersen JC, Dhar JP. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus. Lupus. 2015 Jun;24(7):746-50. DOI 10.1177/0961203314559632.
(2) Magnano L, Enríquez H, Esteve J, Cervera R, Espinosa G. Effectiveness of thrombopoietin-receptor agonists in the treatment of refractory immune thrombocytopenia associated to systemic lupus erythematosus. J Rheumatol. 2014 Sep;41(9):1895-6. DOI 10.3899/jrheum.140080.
(3) Diz-Küçükkaya R, López JA. Thrombocytopenia. In: Kaushansky K, Lichtman MA, Prchal JT, Levi MM, Press OW, Burns LJ, et al, editors. Williams Hematology, 9e [internet]. New York: McGraw-Hill Education; 2015 [cited 2019 Jan 4]. Available from: https://cutt.ly/bkj59jb
(4) Kuwana M, Kaburaki J, Okazaki Y, Miyazaki H, Ikeda Y. Two types of autoantibody-mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2006 Jul;45(7):851-4. DOI 10.1093/rheumatology/kel010.
(5) Nplate. Epar - Product Information Ema.europa.eu. 2019 [internet]. [Cited 2019 Jan 9]. Available from: https://cutt.ly/6kUWfVD
(6) Colombia. Comisión revisora sala especializada de medicamentos y productos biológicos. Bogotá: INVIMA; 2017.
(7) Nplate – Label. Accessdata.fda.gov. 2009 [internet]. [Cited 2019 Jan 9]. Available from: https://cutt.ly/dkUQKY5
(8) Promacta FDA. Accessdata.fda.gov. 2015 [internet]. [Cited 2019 Jan 9]. Available from: https://cutt.ly/QkUWVpB
(9) Colombia. Resolución No. 2017026251 DE 28 de junio de 2017 Por la cual se concede La renovación de un Registro Santitario. Bogotá: INVIMA; 2017.
(10) Revolade, INN-eltrombopag. Ec.europa.eu. 2017 [internet]. [Cited 2019 Jan 9]. Available from: https://cutt.ly/rkUW7zo
(11) Hepburn AL, Narat S, Mason JC. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology (Oxford). 2010 Dec;49(12):2243-54. DOI 10.1093/rheumatology/keq269.
(12) Cuker A, Neunert CE. How I treat refractory immune thrombocytopenia. Blood. 2016 Sep 22;128(12):1547-54. DOI 10.1182/blood-2016-03-603365.
(13) Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA) [internet]. [Cited 2019 Jan 4]. Available from: https://cutt.ly/MkkgNpd
(14) Scheinberg P, Singulane CC, Barbosa LSG, Scheinberg M. Successful platelet count recovery in lupusassociated thrombocytopenia with the thrombopoietin agonist eltrombopag. Clin Rheumatol. 2014 Sep;33(9):1347–9. DOI 10.1007/s10067-014-2600-8.
(15) Tomov S, Lazarchick J, Self SE, Bruner ET, Budisavljevic MN. Kidney-limited thrombotic microangiopathy in patients with SLE treated with romiplostim. Lupus. 2013 Apr;22(5):504-9. DOI 10.1177/0961203313477900.
(16) Jung JH, Soh MS, Ahn YH, Um YJ, Jung JY, Suh CH, et al. Thrombocytopenia in Systemic Lupus Erythematosus: Clinical Manifestations, Treatment, and Prognosis in 230 Patients. Medicine (Baltimore). 2016 Feb;95(6):e2818. DOI 10.1097/MD.0000000000002818.
(17) Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D’Cruz D, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford). 2018 Jan 1;57(1):e1-e45. DOI 10.1093/rheumatology/kex286.
(18) Zhao H, Li S, Yang R. Thrombocytopenia in patients with systemic lupus erythematosus: significant in the clinical implication and prognosis. Platelets. 2010;21(5):380-5. DOI 10.3109/09537101003735564.
(19) Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011 Apr 21;117(16):4190-207. DOI 10.1182/blood-2010-08-302984.
(20) Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017 May 25;129(21):2829-35. DOI 10.1182/blood-2017-03-754119.
(21) Khan AM, Mydra H, Nevarez A. Clinical Practice Updates in the Management of Immune Thrombocytopenia. P T Peer-Rev J Formul Manag. 2017 Dec;42(12):756–63.
(22) Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010 Jan 14;115(2):168-86. DOI 10.1182/blood-2009-06-225565.
(23) Lusa A, Carlson A. Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: a case series. Lupus. 2018 Sep;27(10):1723-1728. DOI 10.1177/0961203318770023.
(24) Portal.guiasalud.es. 2018. Guía de Práctica Clínica sobre Lupus Eritematoso Sistémico [internet]. [Cited 2019 Jan 4]. Available from: https://cutt.ly/FkUEvvV
(25) Vasoo S, Thumboo J, Fong KY. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil. Lupus. 2003;12(8):630-2. DOI 10.1191/0961203303lu417cr.
(26) Blasco L. Hydroxycloroquine alone for severe immune thrombocytopenic purpura associated with systemic lupus erythematosus. Lupus. 2013 Jun;22(7):752–3.
(27) Lee JW, Kim HA, Sung JM, Suh CH. Successful treatment of refractory immune thrombocytopenia with anti-CD20 antibody in a patient with systemic lupus erythematosus. Lupus. 2010 Feb;19(2):227-8. DOI 10.1177/0961203309345723.
(28) Gudbrandsdottir S, Frederiksen H, Hasselbalch H. Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. Platelets. 2012;23(6):423-9. DOI 10.3109/09537104.2011.634931.
(29) Alkaabi JK, Alkindi S, Riyami NA, Zia F, Balla LM, Balla SM. Successful treatment of severe thrombocytopenia with romiplostim in a pregnant patient with systemic lupus erythematosus. Lupus. 2012 Dec;21(14):1571-4. DOI 10.1177/0961203312463621.
(30) LaMoreaux B, Barbar-Smiley F, Ardoin S, Madhoun H. Two cases of thrombosis in patients with antiphospholipid antibodies during treatment of immune thrombocytopenia with romiplostim, a thrombopoietin receptor agonist. Semin Arthritis Rheum. 2016 Feb;45(4):e10-2. DOI 10.1016/j.semarthrit.2015.07.008.
(31) Guitton Z, Terriou L, Lega JC, Nove-Josserand R, Hie M, Amoura Z. Risk of thrombosis with anti-phospholipid syndrome in systemic lupus erythematosus treated with thrombopoietin-receptor agonists. Rheumatology (Oxford). 2018 Aug 1;57(8):1432-1438. DOI 10.1093/rheumatology/key119.
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Universidad de Antioquia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Papers published in the journal are available for use under the Creative Commons license, specifically Attribution-NonCommercial-ShareAlike 4.0 International.
The papers must be unpublished and sent exclusively to the Journal Iatreia; the author uploading the contribution is required to submit two fully completed formats: article submission and authorship responsibility.
